

Annexure I**Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

S. No.	Particulars	Description
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Senn Chemicals AG is a Swiss Corporation registered with the commercial register of the canton of Zurich, Switzerland, domiciled at Guido Senn-Strasse 1, 8157 Dielsdorf, Switzerland.</p> <p>Founded in 1963, It is a privately held Peptide CDMO company that specializes in custom peptide development and manufacturing, supporting global clients across Pharmaceuticals, Cosmetics and Theragnostic industries, from early development to commercial production.</p> <p>The target entity has expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS) and offers development and manufacturing services for peptides, peptide fragments, and amino acid derivatives (AAD).</p> <p>The target entity had estimated sales of CHF 19.6 million in the calendar year (CY) 2024.</p>
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired.</p> <p>If yes, the nature of interest and details thereof and whether the same is done at “arms-length”</p>	<p>No, the acquisition does not fall within the related party transaction.</p> <p>The Promoter/ Promoter group/ group companies have no interest in the target entity.</p>
3.	The industry to which the entity being acquired belongs	Pharmaceuticals and Chemicals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>By integrating the target entity’s capabilities with Granules (the Company) expertise in large-scale, cost-efficient manufacturing, the Company aim to become a key player in peptide-based applications across industries, spanning the entire value chain from AADs and Peptide fragments to peptide-based drugs.</p> <p>The business of the target entity is not outside the main line of business of the Company.</p>

5.	Brief details of any governmental or regulatory approvals required for the acquisition	<p>The proposed acquisition shall be conducted in accordance with the Swiss Code of Obligations (CO).</p> <p>Furthermore, as the target entity holds real estate assets in Switzerland, the transaction is subject to the provisions of Lex Koller (Swiss Federal Act on the Acquisition of Real Estate by Persons Abroad).</p>
6.	The indicative time period for completion of the acquisition	The transaction is expected to be completed in the first half of calendar year 2025.
7.	Nature of consideration- whether cash consideration or share swap and details of the same.	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	The cost of acquisition is CHF 20 million equivalent to INR 1,925 million (approximately) and excluding applicable charges & expenses.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	100% equity stake in the target entity shall be acquired upon completion of the acquisition.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, the country in which the acquired entity has presence and any other significant information (in brief)	<p>Senn Chemicals AG, founded in 1963 is headquartered in Dielsdorf, Switzerland. It operates a GMP certified manufacturing facility and has one R&D facility and one administration and logistics building.</p> <p>The target entity develops and manufactures peptides, peptide fragments and amino acid derivatives for the pharmaceutical, cosmetics and theragnostic industries.</p> <p>The target entity recorded annual revenues of CHF 26.3 million in CY22, CHF 26.9 million in CY23 and CHF 19.6 million in CY24 (estimated).</p>

Annexure: II

Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

S.No.	Particulars	Description
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>The name of the proposed Wholly-owned Subsidiary (“WOS”) will be as may be approved by the Ministry of Corporate Affairs (“MCA”), Government of India.</p> <p>The Company shall be incorporated with an authorized Share capital of Rs. 500 Crores and a paid-up Share capital of Rs. 200 crores.</p> <p>Size/Turnover: Not applicable</p>
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired.</p> <p>If yes, the nature of interest and details thereof and whether the same is done at “arms-length”</p>	<p>The proposed WOS will be a related party of the Company upon incorporation thereof.</p> <p>Save and except as mentioned above, the promoter/ promoter group/ group companies are not interested in the proposed WOS.</p>
3.	The industry to which the entity being acquired belongs	Pharmaceuticals and Chemicals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>The proposed WOS will acquire 100 % equity stake in M/s. Senn Chemicals AG.</p> <p>It will develop and manufacture pharmaceutical products especially focusing on peptides, peptide fragments and amino acid derivatives for the pharmaceutical, cosmetics and theragnostic industries.</p> <p>The business of the proposed WOS is not outside the main line of business of the Company.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	The incorporation of the proposed WOS is subject to the approval of the relevant statutory/regulatory authorities as may be applicable in India.

6.	The indicative time period for completion of the acquisition	The incorporation of the proposed WOS will be completed subject to receipt of approvals of the statutory/regulatory authorities as may be applicable.
7.	Nature of consideration- whether cash consideration or share swap and details of the same.	Subscription of shares in the proposed WOS will be by way of cash consideration.
8.	Cost of acquisition or the price at which the shares are acquired	The Company will be paying cash consideration to the proposed WOS towards a subscription of 100% shareholding.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, the country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable. The WOS is proposed to be incorporated.